echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Towards precision and intelligence, minimally invasive surgery adds value to the treatment of early-stage lung cancer

    Towards precision and intelligence, minimally invasive surgery adds value to the treatment of early-stage lung cancer

    • Last Update: 2022-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lung cancer is the most common type of cancer in China.


    Lung cancer is the most common type of cancer in China.


    Early diagnosis and early treatment move towards precise intelligence Early diagnosis and early treatment move towards precise intelligence

    Surgery is the standard treatment for early-stage lung cancer.


    Surgery is the standard treatment for early-stage lung cancer.


    Zhao Heng, Honorary Director of the Thoracic Surgery Department of Shanghai Chest Hospital and Standing Committee Member of the Thoracic and Cardiovascular Surgery Branch of the Chinese Medical Association, said: " The early diagnosis and early treatment of lung cancer is being upgraded to intelligence and precision


    Different from most of the current lung cancer science popularization on the market, which is mainly based on explanations, doctors who participate in " lung's supplementary advice" not only " move the mouth " but also " hands - on " , and intuitively visualize some of the surgical techniques under the microscope in the minimally invasive surgical treatment of lung cancer.


    The lung is a human organ with a complex structure.


    Many well-known experts including Professor Zhao Heng and Li Hecheng, Director of Thoracic Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University, Zhou Min, Deputy Director of Department of Respiratory and Critical Care Medicine, Ruijin Hospital, and Gu Ye, Deputy Director of Endoscopy Center of Shanghai Pulmonary Hospital Affiliated to Tongji University.


    Image: Roundtable discussion session

    Image: Roundtable discussion session

    Double support, add a buff to life

    Double support, add a buff to life Double support, add a buff to life

    Li Hecheng, director of thoracic surgery at Ruijin Hospital, said: "For popular science activities such as " lung ' assist ' good words, the most needed information is to encourage the public - especially those with high-risk factors such as family history and smoking history - to participate in screening.


    Li Hecheng, director of thoracic surgery at Ruijin Hospital, said: "For popular science activities such as " lung ' assist ' good words, the most needed information is to encourage the public - especially those with high-risk factors such as family history and smoking history - to participate in screening.


    Zhou Min, deputy director of the Department of Respiratory and Critical Care Medicine at Ruijin Hospital, said: " For some patients with specific stages, after undergoing surgical resection, they also need to receive adjuvant drug therapy, such as adjuvant chemoradiotherapy, adjuvant targeted therapy, adjuvant Immunotherapy, etc.


    In addition to doctors and the media, the series of " Lungs Helping Good Words " also gathered two key industrial forces of medical technology and pharmaceuticals .


    At the launching ceremony, Shan Yong, Vice President of Medtronic Innovative Surgery China, said: " In addition to providing surgeons with various surgical tools, Medtronic Innovative Surgery has been committed to breaking through industry boundaries around major diseases, building a diagnosis and treatment ecosystem, and improving patients.


    Photo: Mr.


    Photo: Mr.


    Zhen Zhicheng, head of the lung cancer treatment field of Roche Pharmaceuticals in China, said: " Roche has always adhered to the concept of ' the needs of patients first ' and has been rooted in the field of lung cancer for a long time, targeting multiple targets such as lung cancer targeted therapy, tumor anti-angiogenesis, and lung cancer immunotherapy.


    Picture: Mr.
    Zhen Zhicheng speaking

    Picture: Mr.
    Zhen Zhicheng speaking

    Zhang Wei, senior business director of Medtronic's Innovative Surgical Growth Platform Division, and Hou Huitao, head of Roche's China Lung Cancer Ecological Immunity Market, also participated in the launching ceremony
    .

    Zhang Wei, senior business director of Medtronic's Innovative Surgical Growth Platform Division, and Hou Huitao, head of Roche's China Lung Cancer Ecological Immunity Market, also participated in the launching ceremony
    .


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.